10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
Allogene Therapeutics Inc. (ALLO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Wildcat Capital Management Leonard A. Potter | 2,920,787 | $4,264,349 | 2.28% | |
| 2. | Bourgeon Capital John Zaro | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.90 | 1,724,137 | Director | 1,724,137 | 2024-05-16 | Filing | |
| $3.60 | 190 | 819,590 | 2024-01-30 | Filing | ||
| $12.60 | 15,000 | 258,885 | 2022-01-12 | Filing | ||
| $12.60 | 155,039 | 195,039 | 2022-01-12 | Filing | ||
| $47.00 | 106,382 | 1,798,163 | 2020-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.41 | 9,601 | Officer | 130,663 | 2025-04-21 | Filing | |
| $1.96 | 46,668 | Officer, Director | 5,276,569 | 2025-03-14 | Filing | |
| $1.98 | 5,488 | Officer | 218,507 | 2025-03-14 | Filing | |
| $2.43 | 13,313 | Director | 144,316 | 2025-02-18 | Filing | |
| $1.71 | 6,404 | Officer | 587,848 | 2025-02-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,932,906 | $26,182,043 | 0% | |
| 2. | 8,067,553 | $11,778,627 | 0% | |
| 3. | 5,853,974 | $8,546,802 | 0% | |
| 4. | 4,931,840 | $7,200,486 | 0.01% | |
| 5. | 1,798,163 | $2,625,318 | 19.25% |
News See All
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript
Operator: Hello. Thank you for standing by and welcome to Allogene Therapeutics fourth quarter and full year 2024 conference call.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call. After the speakers' presentation, there will be a question-and-answer session.
7 Best Rising Penny Stocks To Invest In Now
In an episode of Market Storylines on the Inside the Icehouse Podcast feed by Intercontinental Exchange, Jay Woods, Chief Global Strategist at Freedom Capital Markets, discussed Fed rate cuts and the ...
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Top 10 Small-Cap Stocks with Highest Upside Potential
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Allogene Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode.
5 Best Penny Stocks to Buy According to Billionaire Ken Griffin
In this article, we will take a look at the 5 best penny stocks to buy according to billionaire Ken Griffin.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode.
5 Best Rising Penny Stocks To Buy
Monopar Therapeutics (NASDAQ:MNPR) recently jumped after the company reported positive preclinical data for its MNPR-101 program.